EA200870361A1 - Интраназальное или ингаляционное введение виросом - Google Patents

Интраназальное или ингаляционное введение виросом

Info

Publication number
EA200870361A1
EA200870361A1 EA200870361A EA200870361A EA200870361A1 EA 200870361 A1 EA200870361 A1 EA 200870361A1 EA 200870361 A EA200870361 A EA 200870361A EA 200870361 A EA200870361 A EA 200870361A EA 200870361 A1 EA200870361 A1 EA 200870361A1
Authority
EA
Eurasian Patent Office
Prior art keywords
influenza
composition
intranasal
reconstituted
virosomes
Prior art date
Application number
EA200870361A
Other languages
English (en)
Other versions
EA014532B1 (ru
Inventor
Александр Й. Керстен
Лисия Герез
Питер Й. Схун
Йозеф Й.П. Наута
Дорин Х. Ван Рейнек Леиссиус
Original Assignee
Солвей Байолоджикалз Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Байолоджикалз Б.В. filed Critical Солвей Байолоджикалз Б.В.
Publication of EA200870361A1 publication Critical patent/EA200870361A1/ru
Publication of EA014532B1 publication Critical patent/EA014532B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение представляет композицию гриппозных виросом, содержащую восстановленные оболочки указанного вируса, где вирусные оболочки полностью получены из гриппозных вирусных частиц, где к восстановленным виросомам не добавлены липиды из внешних источников, где виросомы содержат антигены гриппа гемагглютинин и/или нейраминидазу или их производные, где к композиции не добавлены отдельные адъюванты и/или иммуностимуляторы и где композиция предназначена для интраназального или ингаляционного введения, при этом композиция характеризуется тем, что однократное интраназальное или ингаляционное введение человеку является достаточным для индукции системного иммунного ответа, и/или локального иммунного ответа, и/или ответа цитотоксических лимфоцитов против указанных антигенов вируса гриппа, причем системный ответ находится в соответствии с критериями СНМР для вакцин против гриппа, и доза гемагглютинина на вирусный штамм при интраназальном или ингаляционном введении меньше или равна 30 мкг. Изобретение также представляет применение восстановленных гриппозных виросом для промышленного производства указанной композиции и, соответственно, промышленного производства вакцинных составов.
EA200870361A 2006-03-22 2007-03-21 Интраназальное или ингаляционное введение виросом EA014532B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78446206P 2006-03-22 2006-03-22
EP06111534 2006-03-22
PCT/EP2007/052690 WO2007107585A1 (en) 2006-03-22 2007-03-21 Intranasal influenza vaccine based on virosomes

Publications (2)

Publication Number Publication Date
EA200870361A1 true EA200870361A1 (ru) 2009-02-27
EA014532B1 EA014532B1 (ru) 2010-12-30

Family

ID=38038698

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870361A EA014532B1 (ru) 2006-03-22 2007-03-21 Интраназальное или ингаляционное введение виросом

Country Status (21)

Country Link
EP (2) EP2158921B1 (ru)
JP (1) JP5285595B2 (ru)
KR (1) KR20090016659A (ru)
AR (1) AR059972A1 (ru)
AT (2) ATE451931T1 (ru)
AU (1) AU2007228736B2 (ru)
BR (1) BRPI0709864A2 (ru)
CA (1) CA2646895A1 (ru)
DE (1) DE602007003815D1 (ru)
DK (2) DK2158921T3 (ru)
EA (1) EA014532B1 (ru)
ES (2) ES2338382T3 (ru)
HR (2) HRP20100144T1 (ru)
IL (1) IL193840A (ru)
MY (1) MY142996A (ru)
NO (1) NO20084452L (ru)
PL (2) PL1996229T3 (ru)
PT (2) PT1996229E (ru)
SA (1) SA07280116B1 (ru)
SI (2) SI1996229T1 (ru)
WO (1) WO2007107585A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010012045A1 (en) * 2008-08-01 2010-02-04 Gamma Vaccines Pty Limited Influenza vaccines
EP2650362A4 (en) * 2010-11-02 2014-10-01 López Hector Manuel Zepeda NEW VACCINES AGAINST PANDEMIC INFLUENZA A / H1N1 VIRUS
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
EP1447080A1 (en) * 2003-02-13 2004-08-18 Bestewil Holding B.V. Method for producing virosome-like particles
AR056245A1 (es) * 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante

Also Published As

Publication number Publication date
PT2158921E (pt) 2012-03-27
EP1996229A1 (en) 2008-12-03
WO2007107585A1 (en) 2007-09-27
DE602007003815D1 (en) 2010-01-28
ES2375436T3 (es) 2012-02-29
CA2646895A1 (en) 2007-09-27
HRP20100144T1 (hr) 2010-04-30
SI2158921T1 (sl) 2012-03-30
IL193840A0 (en) 2011-08-01
BRPI0709864A2 (pt) 2011-07-26
DK1996229T3 (da) 2010-05-03
SI1996229T1 (sl) 2010-04-30
EP2158921B1 (en) 2012-01-04
EP2158921A1 (en) 2010-03-03
AR059972A1 (es) 2008-05-14
PL2158921T3 (pl) 2012-06-29
IL193840A (en) 2011-10-31
DK2158921T3 (da) 2012-05-07
JP5285595B2 (ja) 2013-09-11
EA014532B1 (ru) 2010-12-30
ES2338382T3 (es) 2010-05-06
MY142996A (en) 2011-02-14
EP1996229B1 (en) 2009-12-16
PL1996229T3 (pl) 2010-05-31
NO20084452L (no) 2008-10-22
KR20090016659A (ko) 2009-02-17
JP2009530351A (ja) 2009-08-27
PT1996229E (pt) 2010-03-16
ATE451931T1 (de) 2010-01-15
HRP20120013T1 (hr) 2012-01-31
ATE539766T1 (de) 2012-01-15
ES2375436T8 (es) 2012-03-15
SA07280116B1 (ar) 2010-10-19
AU2007228736B2 (en) 2011-12-15
AU2007228736A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
Sambhara et al. Heterosubtypic Immunity against Human Influenza A Viruses, Including Recently Emerged Avian H5 and H9 Viruses, Induced by FLU–ISCOM Vaccine in Mice Requires both Cytotoxic T-Lymphocyte and Macrophage Function
Quiñones-Parra et al. Universal immunity to influenza must outwit immune evasion
Geeraedts et al. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs
PH12015501482A1 (en) Nasal influenza vaccine composition
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
DE122011100053I1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung.
MY126588A (en) Intranasal influenza virus vaccine
JP2004527264A5 (ru)
JP2013126989A5 (ru)
JP2009539965A5 (ru)
WO2007124479A3 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
MA35414B1 (fr) Formulations de vaccin parenteral contre un norovirus
Budimir et al. Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration
Dong et al. Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice
AU2011280259A8 (en) Influenza vaccine
Vemula et al. Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time
WO2006045532A3 (en) Virosome particles comprising antigens from influenza virus and hepatitis b virus
EA200870361A1 (ru) Интраназальное или ингаляционное введение виросом
RU2014140168A (ru) Улучшенная вакцинация против гриппа
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
WO2006062637A3 (en) Influenza vaccination
Cao et al. Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice
Bhatnagar et al. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice
EA201070014A1 (ru) Внутрикожная вакцина против гриппа

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU